Checkpoint Inhibitor Induced Colitis and Arthritis -Immunomodulation With IL-6 Blockade and Exploration of Disease Mechanisms

Inclusion Criteria:

* Signed informed consent
* Subjects must have signed and dated an IEC approved written informed consent form in accordance with regulatory and institutional guidelines. This must be obtained before the performance of any protocol related procedures that are not part of normal subject care
* Subjects must be willing and able to comply with scheduled visits, treatment schedule, laboratory testing, and other requirements of the study
* Patients with solid tumors treated with PD-1, PD-L1 and /or CTLA-4 inhibitors
* Diarrhea and/or colitis CTCAE grade ˃ 1 and/or arthritis CTCAE grade ˃ 1 induced by PD-1, PD-L1 and /or CTLA-4 inhibitors
* Age 18 years and older
* ECOG/WHO Performance Status (PS) 0-1, PS of 2 due to ongoing irAEs is allowed
* White blood cell count (WBC) ≥ 2 x 10⁹/L and/or absolute neutrophil count (ANC) ≥ 1.0 x 10⁹/L
* Platelet count ≥ 50 x 10⁹/L
* Serum bilirubin ≤ 1.5 x upper limit of normal (ULN)
* ASAT/ALAT ≤ 5 x ULN

Exclusion Criteria:

* History of allergy to study drug component
* Patients should be excluded if they have a condition and/or other irAEs requiring systemic treatment with either corticosteroids (\> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of study drug administration
* Females of childbearing potential or males of reproductive potential who are not willing to use an effective method of contraception, such as oral, injected, or implanted hormonal methods of contraception, intrauterine device or intrauterine system, condom or occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam, gel, film, cream, suppository, male sterilization, or true abstinence throughout study and for a minimum of 3 months after study drug therapy.